Search Results - "Galka, Amy"

Evaluation of endo- and exo-aryl-substitutions and central scaffold modifications on diphenyl substituted alkanes as 5-lipoxygenase activating protein inhibitors by Chu, Lin, Armstrong, Helen M., Chang, Linda L., Cheng, Amy F., Colwell, Lawrence, Cui, Jisong, Evans, Jilly, Galka, Amy, Goulet, Mark T., Hayes, Nancy, Lo, Jane, Menke, John, Ok, Hyun O., Ondeyka, Debra L., Patel, Minal, Quaker, Grace M., Sings, Heather, Witkin, Stephanie L., Zhao, Annie, Ujjainwalla, Feroze

“…The investigation of endo and exo-aryl substitutions and the discovery of the tert-butyl group as a central scaffold on the novel class of FLAP inhibitors are…”
Get full text

Cyclization of unsaturated amides with triflic anhydride and samarium diiodide by McDonald, Chriss E, Galka, Amy M, Green, Ahren I, Keane, Joseph M, Kowalchick, Jennifer E, Micklitsch, Christopher M, Wisnoski, David D

“…A new approach to the generation of acyl radical equivalents has been developed. Treatment of amides with triflic anhydride followed by samarium diiodide…”
Get full text

Synthesis and structure–activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists by Dzierba, Carolyn D., Sielecki, Thais M., Arvanitis, Argyrios G., Galka, Amy, Johnson, Tricia L., Takvorian, Amy G., Rafalski, Maria, Kasireddy-Polam, Padmaja, Vig, Shikha, Dasgupta, Bireshwar, Zhang, Ge, Molski, Thaddeus F., Wong, Harvey, Zaczek, Robert C., Lodge, Nicholas J., Combs, Andrew P., Gilligan, Paul J., Trainor, George L., Bronson, Joanne J., Macor, John E.

“…Pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones were evaluated as corticotropin-releasing factor-1 receptor antagonists. The synthesis, SAR studies and…”
Get full text

Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists by Armstrong, Helen E., Galka, Amy, Lin, Linus S., Lanza, Thomas J., Jewell, James P., Shah, Shrenik K., Guthikonda, Ravi, Truong, Quang, Chang, Linda L., Quaker, Grace, Colandrea, Vincent J., Tong, Xinchun, Wang, Junying, Xu, Sherry, Fong, Tung M., Shen, Chun-Pyn, Lao, Julie, Chen, Jing, Shearman, Lauren P., Stribling, D. Sloan, Rosko, Kimberly, Strack, Alison, Ha, Sookhee, der Ploeg, Lex Van, Goulet, Mark T., Hagmann, William K.

“…Sulfonamide analogues of the potent CB1R inverse agonist 2 (Taranabant) were optimized for CB1R activity. Sulfonamide analogues of the potent CB1R inverse…”
Get full text